The FDA recently approved an ORAL therapy, Ekterly (sebetralstat) from KalVista Pharmaceuticals, indicated as an oral treatment for acute hereditary angioedema (HAE) attacks in patients
The latest round of price negotiations has captured the attention of industry insiders and consumers alike, signaling potential shifts across the market landscape. As companies
This Report takes a deep dive into the complex world of rare and orphan drugs – and the unique challenges of how they’re priced. This
The FDA recently approved a new infused therapy, Datroway (detumomab deruxtecan-dlnk) from AstraZeneca, indicated for the treatment of adult patients with unresectable or metastatic, hormone
The FDA recently approved a sub-q therapy, Yeztugo (lenacapavir) from Gilead, indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in
The FDA recently approved Andembry (garadacimab-gxii) from CSL for the prophylactic treatment of hereditary angioedema (HAE). This approval marks a significant milestone as Garadacimab is
Are you familiar with the term “Virtual Patients”? As the field of CGT (cell and gene therapy) rapidly evolves, understanding this concept will be increasingly
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases
Recent Reports have discussed the development of cell and gene therapy (CGT) and its potential to alter medical treatment approaches. Today’s article indicates that CGT
The FDA recently approved a new therapy, Enflonsia (clesrovimab-cfor) from Merck & CO., indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract
